VAXXED: And the winner is... with OneVentures and Ose Immunotherapeutics
Description
Moderna and BioNTech are getting all of the attention with their phase 3 clinical trials for lung cancer and melanoma. But someone else is already further ahead.
French company Ose Immunotherapeutics has already done a phase 3 study for non small cell lung cancer, and if the final run of work confirms that data it will have the first cancer vaccine on the market in 2028.
And it's results like those emerging from Ose that are inspiring investors to start getting set for a cancer vaxxed future.
In our final episode of VAXXED we feature OneVentures partner Dr. Jeannie Joughin and Ose Immunotherapeutics CEO Nicolas Poirier.
Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.
United States
